For example, the administration of TRPV4 antagonists improves negative outcomes in animal models of pulmonary edema, blood‒retinal and blood‒brain barrier disruption, and peripheral neuropathy [57,58], and treatment with the TRPV4-specific antagonist AB159908 reduces Ca2+ inflow into fibroblasts, blocks collagen remodeling, and maintains the balance of ECM components [59]. The gene discussed is TRPV4; the disease is pulmonary edema.